Breakfast Technical Briefing on Biotech Stocks — Cytori Therapeutics, Sorrento Therapeutics, Marinus Pharma, and NewLink Genetics

Cytori Therapeutics

San Diego, California headquartered Cytori Therapeutics Inc.’s shares dropped 2.15%, closing Monday’s trading session at $0.39. The stock recorded a trading volume of 296,136 shares. The Company’s shares have advanced 6.39% over the previous three months. The stock is trading 4.90% below its 50-day moving average. Additionally, shares of Cytori Therapeutics, which develops cellular therapeutics for specific diseases and medical conditions, have a Relative Strength Index (RSI) of 41.44. 

On November 02nd, 2017, Cytori Therapeutics announced that it will issue its Q3 earnings release on November 09th, 2017, at approximately 4:30 p.m. ET. The Company will provide a live webcast of its financial results and business update on at 5:30 p.m. ET that same day. The webcast will be available both live and by replay two hours after the call under the “Webcasts” section of the Company’s website. See our free and comprehensive research report on CYTX at:

Sorrento Therapeutics

On Monday, shares in San Diego, California-based Sorrento Therapeutics Inc. recorded a trading volume of 1.26 million shares, which was above their three months average volume of 1.09 million shares. The stock edged 11.54% higher, ending the day at $2.90. The Company’s shares have surged 61.11% in the past month and 48.72% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 35.20% and 7.40%, respectively. Furthermore, shares of Sorrento Therapeutics, which engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide, have an RSI of 61.49.  SRNE free research report is just a click away at:

Marinus Pharmaceuticals

Radnor, Pennsylvania-based Marinus Pharmaceuticals Inc.’s stock finished the day 11.15% higher at $6.88 with a total trading volume of 1.36 million shares. The Company’s shares have skyrocketed 215.60% in the previous three months and 581.19% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 39.64% and 188.78%, respectively. Additionally, shares of Marinus Pharma, which focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders, have an RSI of 65.55. 

On October 31st, 2017, Marinus Pharma reported its financial results for the three months ended September 30th, 2017. R&D expenses for Q3 2017 decreased to $2.6 million; G&A expenses were $1.6 million; and cash used in operating activities decreased to $14.3 million. At September 30th, 2017, the Company had cash, cash equivalents, and investment balances of $62.9 million. Sign up for your complimentary report on MRNS at:

NewLink Genetics

Shares in Ames, Iowa headquartered NewLink Genetics Corp. ended yesterday’s session 1.24% higher at $8.98. The stock recorded a trading volume of 1.12 million shares. The Company’s shares have advanced 27.20% over the previous three months. The stock is trading 13.86% below its 50-day moving average. Moreover, shares of NewLink Genetics, which focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer, have an RSI of 27.51. 

On October 13th, 2017, research firm Bank of America/ Merrill initiated a ‘Buy’ rating on the Company’s stock, with a target price of $22 per share.

On October 30th, 2017, NewLink Genetics announced that indoximod, its leading drug development candidate, was granted orphan-drug designation by the U.S. Food and Drug Administration for the treatment of patients with Stage IIb-IV melanoma. The Company is currently evaluating indoximod in multiple combination studies for patients with various types of cancer including melanoma, acute myeloid leukemia, pancreatic cancer, and prostate cancer.  Register for free on and download the latest research report on NLNK at:

Daily Stock Tracker:

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Powered by WPeMatico

Comments are closed.